Bruker (NASDAQ:BRKR) had its target price trimmed by SVB Leerink from $58.00 to $46.00 in a research note issued to investors on Monday morning, The Fly reports. The brokerage currently has an outperform rating on the medical research company’s stock. SVB Leerink also issued estimates for Bruker’s Q1 2020 earnings at $0.30 EPS, Q2 2020 earnings at $0.36 EPS, Q3 2020 earnings at $0.45 EPS, Q4 2020 earnings at $0.53 EPS, FY2020 earnings at $1.64 EPS and FY2021 earnings at $1.95 EPS.
Other equities research analysts have also recently issued research reports about the company. BidaskClub cut Bruker from a hold rating to a sell rating in a research report on Tuesday, February 4th. Citigroup decreased their target price on Bruker from $52.00 to $40.00 and set a neutral rating for the company in a research report on Friday, March 20th. Barclays raised Bruker from an equal weight rating to an overweight rating and decreased their target price for the stock from $52.00 to $48.00 in a research report on Thursday, March 26th. Needham & Company LLC increased their price objective on Bruker from $62.00 to $63.00 and gave the company a strong-buy rating in a research report on Wednesday, February 19th. Finally, Wells Fargo & Co initiated coverage on Bruker in a research report on Tuesday, January 7th. They issued an overweight rating and a $60.00 price objective for the company. Three analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $47.21.
Bruker stock traded up $2.05 during trading hours on Monday, reaching $33.61. 1,556,800 shares of the company were exchanged, compared to its average volume of 827,713. The firm has a market cap of $5.52 billion, a price-to-earnings ratio of 26.67, a PEG ratio of 2.13 and a beta of 1.48. The company has a current ratio of 2.78, a quick ratio of 1.32 and a debt-to-equity ratio of 0.94. The stock has a 50-day moving average of $42.81 and a 200 day moving average of $46.93. Bruker has a 12 month low of $30.78 and a 12 month high of $54.49.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Norges Bank acquired a new position in shares of Bruker in the fourth quarter valued at $77,325,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Bruker in the fourth quarter valued at $280,000. Pearl River Capital LLC acquired a new position in shares of Bruker in the fourth quarter valued at $202,000. Geode Capital Management LLC raised its stake in shares of Bruker by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 1,476,826 shares of the medical research company’s stock valued at $75,270,000 after purchasing an additional 49,046 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Bruker by 2.7% in the fourth quarter. Alliancebernstein L.P. now owns 1,660,293 shares of the medical research company’s stock valued at $84,625,000 after purchasing an additional 43,765 shares in the last quarter. Institutional investors and hedge funds own 69.49% of the company’s stock.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.